FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
31/10/2023
Voltar para busca
Dado oficial do USPTO
ILLIMIS
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
27
Atualização mais recente
31/10/2023
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
5, 42
Data de depósito
17/03/2022
Data de registro
04/07/2023
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
04/07/2023
Última transação
04/07/2023
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
5
Tipo de titular
03
Localização do titular
KR
Examinador
THOMAS, JULIE
Unidade examinadora
L70
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
Illimis Therapeutics, Inc.
Representantes
Jong Park The PL Law Group, PLLC
Classificação técnica
Classes Nice
Classe 5Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical preparations for the treatment of auto-immune diseases; pharmaceutical agents affecting sensory organs; pharmaceutical agents affecting peripheral nervous system; pharmaceutical preparations for activating cellular function; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations for respiratory organs; pharmaceutical preparations for the prevention of disorders of the nervous system; pharmaceutical preparations for the treatment of cardiovascular disease; pharmaceutical preparations for the treatment of inflammatory diseases; ophthalmic preparations; pharmaceutical preparations for the treatment of eye diseases and conditions; pharmaceutical preparations for the treatment of degenerative brain disease; pharmaceutical preparations for the treatment of brain dysfunction; pharmaceutical preparations for the treatment of stroke; pharmaceutical preparations for the treatment of cerebrovascular disease; pharmaceutical preparations for the treatment of dementia; pharmaceutical preparations for the treatment of Alzheimer's disease; pharmaceutical preparations for use in the treatment of solid tumors and growthshemolytic diseases and disordersamyloidosismetabolic diseases and disorderslupusinflammation and autoimmune diseases and disorders
Classe 42
Pharmaceutical product development; pharmaceutical research and development of medicines in the field of age-related diseases/disorders and degenerative diseases; pharmaceutical research and development of medicines in the field of chronic malady/disease and dysfunction; scientific research for medical purposes in the field of gene therapy; medical scientific research in the field of brain disease; medical scientific research in the field of neurological diseases; biotechnology research and scientific and pharmaceutical research in the antibody field; biological research; scientific research in the field of cancer disease; remote monitoring and quality control inspection for others of active substances in the pharmaceutical research field and scientific analysis of active substances in the pharmaceutical research field; research for quality inspection related to human hygiene management for medical research purposes; scientific and medical research of autoimmune disease; development of pharmaceutical preparations for cell therapy; stem cell collection for medical research; cell processing and culture for medical research; pharmaceutical research and development of medicines in the field of inflammatory disease; pharmaceutical research and development of medicines in the field of eye disease; pharmaceutical research and development of medicines in the field of amyloidosis; consultancy pertaining to pharmacology relating to pharmaceutical quality control; providing information on the research of medical products relating to pharmaceutical quality control
Publicações
Histórico de despachos e eventos da marca no USPTO.
27 publicações encontradas
FICS
FINAL DISPOSITION NOTICE SENT TO IB
06/10/2023
FIMP
FINAL DISPOSITION PROCESSED
06/10/2023
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
04/10/2023
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
04/07/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
04/07/2023
LIME
LIMITATION FROM THE IB EXAMINED AND ENTERED
10/05/2023
GPNX
NOTIFICATION PROCESSED BY IB
25/04/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
18/04/2023
PUBO
PUBLISHED FOR OPPOSITION
18/04/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
05/04/2023
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
05/04/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
29/03/2023
RFNT
REFUSAL PROCESSED BY IB
21/03/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
11/03/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
07/03/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
07/03/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
07/03/2023
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
27/02/2023
RFRR
REFUSAL PROCESSED BY MPU
27/02/2023
LIMG
LIMITATION OF GOODS RECEIVED FROM IB
13/02/2023
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
01/01/2023
CNRT
NON-FINAL ACTION WRITTEN
31/12/2022
DOCK
ASSIGNED TO EXAMINER
29/12/2022
MAFR
APPLICATION FILING RECEIPT MAILED
14/06/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
10/06/2022
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
09/06/2022
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace ILLIMIS ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.